Navigation Links
Abaxis Reports Record Revenues For The Third Quarter Of Fiscal 2013
Date:1/31/2013

UNION CITY, Calif., Jan. 31, 2013 /PRNewswire/ -- Abaxis, Inc. (NasdaqGS: ABAX), a medical products company manufacturing point-of-care blood analysis systems, today reported financial results for the third fiscal quarter ended December 31, 2012.

Record quarterly highlights include:

  • Revenues of $49.8 million, up 32% over last year's comparable quarter.
  • North America revenues of $41.8 million, up 31% over last year's comparable quarter.
  • Medical market revenues of $9.0 million, up 10% over last year's comparable quarter.
  • Veterinary market revenues of $39.9 million, up 40% over last year's comparable quarter.
  • Total medical and veterinary instrument revenues of $14.0 million, up 54% over last year's comparable quarter.
  • Total medical and veterinary instrument sales of 1,818 units, up 52% over last year's comparable quarter.
  • Total medical and veterinary reagent disc sales of $26.7 million, up 31% over last year's comparable quarter.
  • Total medical and veterinary reagent disc sales of 2.1 million units, up 29% over last year's comparable quarter.
  • Other quarterly highlights include:

  • International revenues of $8.0 million, up 33% over last year's comparable quarter.
  • Service revenues from Abaxis Veterinary Reference Laboratories (AVRL) of $1.4 million, up 28% over the second quarter of fiscal 2013.
  • Diluted net income per share of $0.22, compared to $0.13 per share for the same period last year.
  • Quarterly Results:  For the fiscal quarter ended December 31, 2012, Abaxis reported revenues of $49.8 million, as compared with revenues of $37.9 million for the comparable period last year, an increase of 32 percent.  Revenues from sales of instruments, which include chemistry analyzers, hematology instruments, VSpro specialty analyzers and i-STAT analyzers, increased by an aggregate of $4.9 million or 54 percent, over the same period last year.  Revenues from sales of consumables, which include reagent discs, hematology reagent kits, VSpro specialty cartridges, i-STAT cartridges and rapid tests, increased by an aggregate of $6.0 million, or 22 percent, over the same period last year.  Abaxis reported net income of $5.0 million for the fiscal quarter ended December 31, 2012, compared to $2.9 million for the same period last year, an increase of 75 percent.  Abaxis' effective tax rate in the quarter ended December 31, 2012 was 38 percent, compared to 37 percent for the same period last year.  Abaxis reported diluted net income per share of $0.22 (calculated based on 22,341,000 shares) for the three-month period ended December 31, 2012, compared to $0.13 per share (calculated based on 21,990,000 shares) for the same period last year. 

    Nine-Month Results:  For the nine-month period ended December 31, 2012, Abaxis reported revenues of $136.1 million, as compared with revenues of $113.9 million for the comparable period last year, an increase of 19 percent.  Revenues from instrument sales increased by an aggregate of $10.1 million, or 40 percent, over the same period last year.  Revenues from consumables increased by an aggregate of $8.7 million, or 10 percent, over the same period last year.  The company reported net income of $20.8 million, including gain from the company's litigation settlement in the second quarter of fiscal 2013, compared to $8.4 million for the same period last year.  The company's effective tax rate in the nine-month period ended December 31, 2012, was 38 percent, compared to 37 percent for the same period last year.  The company reported diluted net income per share of $0.93 (calculated based on 22,316,000 shares) for the nine-month period ended December 31, 2012, compared to $0.37 per share (calculated based on 22,579,000 shares) for the same period last year. 

    Other Reported Information:  Total sales in the medical market for the third quarter of fiscal 2013 were $9.0 million, an increase of 10 percent, compared to the same period last year.  Medical sales worldwide, excluding sales to the U.S. government, during the third quarter of fiscal 2013 were $8.6 million, an increase of 15 percent, compared to the same period last year.  Total sales in the veterinary market for the third quarter of fiscal 2013 were $39.9 million, an increase of 40 percent, compared to the same period last year.  Total medical and veterinary reagent disc sales for the third quarter of fiscal 2013 were $26.7 million, an increase of 31 percent compared to the same period last year.  Non-cash compensation expense recognized for share-based awards during the third quarter of fiscal 2013 was $1.8 million, compared to $1.5 million for the same period last year.On December 6, 2012, the company's Board of Directors declared a special cash dividend of $1.00 per share on the company's outstanding common stock.  The dividend payment totaling approximately $22.0 million was made on December 28, 2012.

    Clint Severson, chairman and chief executive officer of Abaxis, said, "The financial results of the third quarter of fiscal 2013 were very strong.  We are steadily executing on our strategic plan to drive sales and net income, as total revenues increased 32% and net income increased 75%, compared to last year's third quarter.  Overall we achieved record quarterly reagent disc sales and instrument sales increased at solid double digit rates compared to third quarter of fiscal 2012.  We are particularly pleased and encouraged with the development of our working relationships with our two new distributors, Abbott Point of Care, Inc. and MWI Veterinary Supply, Inc.  These new distribution channels give us entry into markets to which we previously had very little access and expand the universe into which we can embed Abaxis technology.  While we are still in the early stages of working together, we are developing the necessary chemistry between our respective organizations that will ensure long-term success."

    "We are also pleased with the progress achieved in the international markets during the quarter," continued Mr. Severson.  "Sales in both Europe and Asia continued to improve and grew at a 33% rate compared to last year's third quarter.  Although macroeconomic conditions throughout the world continue to be challenging, our dedication to building these markets during these most difficult times is beginning to bear real fruit.  All in all, we had a very solid quarter and we look to finish the year on a strong note in both our veterinary and medical markets."

    Conference CallAbaxis has scheduled a conference call to discuss its results at 4:15 p.m. Eastern Time on Thursday, January 31, 2013.  Participants can dial (877) 317-6789 or (412) 317-6789 to access the conference call, or can listen via a live Internet web cast, which is available in the Investor Relations section of the company's website at http://www.abaxis.com.  A replay of the call will be available by visiting http://www.abaxis.com for the next 30 days or by calling (877) 344-7529 or (412) 317-0088, confirmation code 10024107, through February 7, 2013.  This press release is also available prior to and after the call via Abaxis' website or the Securities and Exchange Commission's website at http://www.sec.gov

    About AbaxisAbaxis develop, manufactures, markets and sells portable blood analysis systems for use in any veterinary or human patient-care setting to provide clinicians with rapid blood constituent measurements.  The system consists of a compact, 5.1 kilogram (11.2 pounds), portable analyzer and a series of single-use plastic discs, called reagent discs that contain all the chemicals required to perform a panel of up to 13 tests on veterinary patients and 14 tests on human patients.  The system can be operated with minimal training and performs multiple routine tests on whole blood, serum or plasma samples.  The system provides test results in less than 12 minutes with the precision and accuracy equivalent to a clinical laboratory analyzer.  The veterinary business also provides to the animal health and research market a line of hematology instruments for point-of-care complete blood counts (CBC), a specialty instrument to screen for and detect clotting disorders and to measure equine fibrinogen levels, a handheld instrument for the rapid assessment of certain critical care tests and rapid point-of-care tests for Heartworm infections, Parvovirus, Giardia and Lyme disease.  Abaxis, through its AVRL division, provides routine laboratory testing as well as specialty testing for veterinarians nationwide.

    Use of Financial MeasuresTo supplement the financial statements presented in accordance with United States generally accepted accounting principles (GAAP), Abaxis uses operating income per share, a non-GAAP financial measure. The presentation of this financial information is not intended to be considered in isolation or as a substitute for, or superior to, the financial information prepared and presented in accordance with GAAP. For more information on this non-GAAP financial measure, refer to the table captioned "Operating Income Per Share" included at the end of this release.  Abaxis defines operating income per share as operating income divided by the weighted average outstanding shares.  Management uses this measure in comparing Abaxis' operating results with historical performance and believes it provides meaningful and comparable information to management and investors to assist in their review of Abaxis' performance relative to prior periods and its competitors.

    Forward Looking StatementsThis press release includes, and our conference call will include, statements that constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Reform Act"), including but not limited to statements related to Abaxis' cash position, financial resources and potential for future growth, market acceptance and penetration of new or planned product offerings, and future recurring revenues and results of operations.  Abaxis claims the protection of the safe-harbor for forward-looking statements contained in the Reform Act.  These forward-looking statements are often characterized by the terms "may," "believes," "projects," "expects," "anticipates," or words of similar import, and do not reflect historical facts.  Specific forward-looking statements contained in this press release or in Abaxis' conference call may be affected by risks and uncertainties, including, but not limited to, those related to losses or system failures with respect to Abaxis' facilities or manufacturing operations, fluctuations in quarterly operating results, dependence on sole suppliers, the market acceptance of Abaxis' products and services, the continuing development of its products, required United States Food and Drug Administration clearance and other government approvals, risks associated with manufacturing and distributing its products on a commercial scale free of defects, risks related to the introduction of new instruments manufactured by third parties, risks associated with competing in the human diagnostic market, risks related to the protection of Abaxis' intellectual property or claims of infringement of intellectual property asserted by third parties and risks related to condition of the United States economy.  Readers should also refer to the section entitled "Risk Factors" in Abaxis' Annual Report on Form 10-K, its most recent Quarterly Report on Form 10-Q and Abaxis' other periodic reports filed with the United States Securities and Exchange Commission.  Forward-looking statements speak only as of the date the statements were made.  Abaxis does not undertake and specifically disclaims any obligation to update any forward-looking statements.

    Financial Tables to FollowABAXIS, INC.Condensed Consolidated Statements of Income(In thousands, except per share data)(Unaudited)Three Months EndedNine Months EndedDecember 31,December 31,2012201120122011Revenues

    $
    49,802

    $
    37,850

    $
    36,074

    $
    3,878Cost of revenues

    23,726

    17,372

    64,026

    52,156Gross profit

    26,076

    20,478

    72,048

    61,722Operating expenses:Research and development 

    3,802

    2,634

    10,348

    9,096Sales and marketing 

    12,373

    9,927

    35,647

    28,414General and administrative

    2,210

    3,280

    10,153

    11,194Gain from legal settlement

    -

    -

    (17,250)

    -Total operating expenses

    18,385

    15,841

    38,898

    48,704Income from operations

    7,691

    4,637

    33,150

    13,018Interest and other income (expense), net

    293

    (91)

    318

    259Income before income tax provision

    7,984

    4,546

    33,468

    13,277Income tax provision

    2,996

    1,696

    12,707

    4,892Net income

    $
    4,988

    $
    2,850

    $
    20,761

    $
    8,385Net income per share:  Basic net income per share

    $
    .23

    $
    .13

    $
    .95

    $
    .38  Diluted net income per share

    $
    .22

    $
    .13

    $
    .93

    $
    .37Shares used in the calculation of net income per share:  Weighted average common shares outstanding - basic

    21,968

    21,672

    21,902

    22,213  Weighted average common shares outstanding - diluted

    22,341

    21,990

    22,316

    22,579ABAXIS, INC.Condensed Consolidated Balance Sheets(Unaudited and in thousands)December 31,March 31,20122012Current assets: Cash and cash equivalents

    $
    47,427

    $
    45,843 Short-term investments

    22,644

    21,689 Receivables, net

    36,094

    30,694 Inventories

    25,069

    19,597 Prepaid expenses and other current assets

    7,067

    5,423 Net deferred tax assets, current

    4,356

    4,151Total current assets 

    142,657

    127,397Long-term investments

    21,712

    23,442Investment in unconsolidated affiliate

    2,613

    2,626Property and equipment, net

    25,512

    24,296Intangible assets, net

    3,515

    3,990Other assets

    97

    85Total assets

    $
    96,106

    $
    81,836Current liabilities: Accounts payable

    $
    ,536

    $
    ,381 Accrued payroll and related expenses

    8,380

    6,336 Accrued taxes

    229

    266 Other accrued liabilities

    2,314

    1,991 Deferred revenue

    1,388

    1,212 Warranty reserve

    993

    1,245Total current liabilities

    24,840

    17,431Non-current liabilities: Deferred rent

    712

    641 Net deferred tax liabilities

    159

    199 Deferred revenue

    3,517

    2,396 Warranty reserve

    473

    601 Notes payable, less current portion

    707

    783Total non-current liabilities

    5,568

    4,620Total liabilities

    30,408

    22,051Shareholders' equity: Common stock

    117,217

    110,063 Retained earnings 

    48,435

    49,697 Accumulated other comprehensive income

    46

    25Total shareholders' equity

    165,698

    159,785Total liabilities and shareholders' equity

    $
    96,106

    $
    81,836Operating Income Per Share(In thousands, except per share data)Three Months EndedNine Months EndedDecember 31,December 31,2012201120122011Shares used in the calculation of operating income per share:  Weighted average common shares outstanding - basic

    21,968

    21,672

    21,902

    22,213  Weighted average common shares outstanding - diluted

    22,341

    21,990

    22,316

    22,579Operating income per share - basic

    $
    .35

    $
    .21

    $
    .51

    $
    .59Operating income per share - diluted

    $
    .34

    $
    .21

    $
    .49

    $
    .58Revenues by Geographic Region(In thousands)Three Months EndedNine Months EndedDecember 31,December 31,2012201120122011North America

    $
    41,797

    $
    31,847

    $
    ,876

    $
    93,540International

    8,005

    6,003

    25,198

    20,338Total revenues

    $
    49,802

    $
    37,850

    $
    36,074

    $
    3,878Revenues by Customer Group(In thousands)Three Months EndedNine Months EndedDecember 31,December 31,2012201120122011Medical Market

    $
    8,977

    $
    8,147

    $
    25,267

    $
    22,636Veterinary Market

    39,865

    28,467

    107,299

    87,684Other

    960

    1,236

    3,508

    3,558Total revenues

    $
    49,802

    $
    37,850

    $
    36,074

    $
    3,878 

     


    '/>"/>
    SOURCE Abaxis, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Abaxis To Report Third Quarter Fiscal Year 2013 Financial Results Thursday, January 31, 2013
    2. Abaxis Declares Special Cash Dividend of $1.00 Per Share
    3. Abaxis, Inc. to Present at 24th Annual Piper Jaffray Healthcare Conference
    4. Abaxis, Inc. to Participate in Sidoti & Companys Inaugural One-on-One Conference
    5. Abaxis, Inc. to Present at the Stephens Fall Investment Conference
    6. Abaxis, Inc. to Present at the Lazard Capital Markets 9th Annual Healthcare Conference
    7. Abaxis Announces Exclusive Distribution Agreement with Abbott
    8. Abaxis Announces the Launch of Kidney Profile Plus Panel
    9. Abaxis, Inc. to Present at UBS Global Life Sciences Conference
    10. Abaxis, Inc. to Present at CL Kings 10th Annual Best Ideas Conference 2012
    11. Abaxis, Inc. to Present at the Morgan Stanley Global Healthcare Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:6/26/2016)... , June 26, 2016 ... care operating models within the health care industry is ... financial efficiency , Deloitte offers a suite of ... business issues impacting efficient cost optimization: labor resource analysis, ... These services facilitate better outcomes and better economics ...
    (Date:6/24/2016)... June 24, 2016  Collagen Matrix, Inc., ("Collagen ... and manufacturing of collagen and mineral based medical ... that Bill Messer has joined the ... further leverage the growing portfolio of oral surgery, ... Bill joins the Collagen Matrix executive team ...
    (Date:6/24/2016)... , June 24, 2016   Bay ... Rehabilitation Network,s Dean Center for Tick Borne ... Medicine and Rehabilitation, MIT Hacking Medicine, University of ... Innovation, today announced the five finalists of ... Lyme disease.  More than 100 scientists, clinicians, researchers, ...
    Breaking Medicine Technology:
    (Date:6/25/2016)... ... 2016 , ... On Friday, June 10, Van Mitchell, Secretary of the Maryland ... iHire in recognition of their exemplary accomplishments in worksite health promotion. , The Wellness ... & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was one of ...
    (Date:6/24/2016)... ... 24, 2016 , ... A recent article published June 14 on ... article goes on to state that individuals are now more comfortable seeking to undergo ... such as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills ...
    (Date:6/24/2016)... ... ... June 19, 2016 is World Sickle Cell Observance Day. In an effort ... holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued a pain ... Disease (SCD) is a disorder of the red blood cells, which can cause episodes ...
    (Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension Association (PHA) ... will receive two significant new grants to support its work to advance research ... anniversary by recognizing patients, medical professionals and scientists for their work in fighting ...
    (Date:6/24/2016)... ... 24, 2016 , ... Dr. Amanda Cheng, an orthodontist ... has extensive experience with all areas of orthodontics, including robotic Suresmile technology, ... , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It can be used ...
    Breaking Medicine News(10 mins):